American Journal of Pediatrics

| Peer-Reviewed |

Development of Pulmonary Hypertension in an Infant Treated With Diazoxide for Hyperinsulinism, a Case Report and Literature Review

Received: Jun. 27, 2015    Accepted: Jul. 20, 2015    Published: Jul. 23, 2015
Views:       Downloads:

Share This Article

Abstract

Congenital hyperinsulinism (CHI) is heterogeneous disorder in the neonatal period characterized by inappropriate insulin secretion in the presence of hypoglycemia. Known etiologies include inactivating mutations of the KATP channel. Its management can be extremely complicated, and may involve medical therapy and surgery. We describe a full term baby male at one month-old without dysmorphic features or congenital anomalies, the baby was presented with asymptomatic hypoglycemia by routine screening at the age of 1.5 hour of life, he was treated with diazoxide for prolonged neonatal hyperinsulinism. Tolerance of diazoxide is usually excellent, but several adverse effects of this drug have been described. During diazoxide therapy he presented with tachycardia and low oxygen saturation, the baby became dyspnoeic with fluid retention and facial edema. Echocardiography showed moderate pulmonary hypertension. Diazoxide was withdrawn, his clinical status and pulmonary hypertension dramatically improved and returned to baseline.

DOI 10.11648/j.ajp.20150101.11
Published in American Journal of Pediatrics ( Volume 1, Issue 1, July 2015 )
Page(s) 1-3
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Previous article
Keywords

Hyperinsulism, Diazoxide, Pulmonary Hypertension

References
[1] Yorifuji T. Congenital hyperinsulinism: current status and future perspectives. Ann Pediatr Endocrinol Metab. 2014; 19(2):57-68.
[2] Arnoux JB, Verkarre V, Saint-Martin C, Montravers F, Brassier A, Valayannopoulos V, Brunelle F, Fournet JC, Robert JJ, Aigrain Y, Bellanné-Chantelot C, de Lonlay P. Congenital hyperinsulinism: current trends in diagnosis and therapy. Orphanet J Rare Dis. 2011;6:63.
[3] Gopal-Kothandapani JS, Hussain K. Congenital hyperinsulinism: Role of fluorine-18L-3, 4 hydroxyphenylalanine positron emission tomography scanning. World J Radiol. 2014 28;6(6):252-260.
[4] Lovvorn HN 3rd, Nance ML, Ferry RJ Jr, Stolte L, Baker L, O'Neill JA Jr, Schnaufer L, Stanley CA, Adzick NS. Congenital hyperinsulinism and the surgeon: lessons learned over 35 years. J Pediatr Surg. 1999;34(5):786-92; discussion 792-793.
[5] Parker JJ, Allen DB. Hypertrophic cardiomyopathy after prolonged diazoxide therapy for hyperinsulinemic hypoglycemia. J Pediatr. 1991;118(6):906-909.
[6] Yildizdas D, Erdem S, Küçükosmanoglu O, Yilmaz M, Yüksel B. Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. Adv Ther. 2008;25(5):515-519.
[7] Price LC, McAuley DF, Marino PS, Finney SJ, Griffiths MJ, Wort SJ. Pathophysiology of pulmonary hypertension in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2012;302(9):L803-815.
[8] Silvani P, Camporesi A Drug-induced pulmonary hypertension in newborns: a review. Curr Vasc Pharmacol. 2007;5(2):129-133. Review.
[9] Demirel F, Unal S, Ç etin II, Esen I, Arasli A. Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide. J Pediatr Endocrinol Metab. 2011;24(7-8):603-605.
[10] Yildizdas D, Erdem S, Küçükosmanoglu O, Yilmaz M, Yüksel B. Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. Adv Ther. 2008;25(5):515-519.
[11] Nebesio TD, Hoover WC, Caldwell RL, Nitu ME, Eugster EA. Development of pulmonary hypertension in an infant treated with diazoxide. J Pediatr Endocrinol Metab. 2007;20(8):939-944.
[12] Senguttuvan R, Saleh M, Wheeler M, Patel Ch, Chin C and Patel P. Diazoxide induced pulmonary hypertension in an infant. Endocrine Society's 96th Annual Meeting and Expo, June 21–24, 2014 – Chicago.
[13] Silvani P, Camporesi A, Mandelli A, Wolfler A, Salvo I. A case of severe diazoxide toxicity. Paediatr Anaesth. 2004;14(7):607-609.
Cite This Article
  • APA Style

    Albahri Ziad, Lukeš Antonín, Mynářová Kateřina, Krylová Kateřina, Al Mawiri Abdul, et al. (2015). Development of Pulmonary Hypertension in an Infant Treated With Diazoxide for Hyperinsulinism, a Case Report and Literature Review. American Journal of Pediatrics, 1(1), 1-3. https://doi.org/10.11648/j.ajp.20150101.11

    Copy | Download

    ACS Style

    Albahri Ziad; Lukeš Antonín; Mynářová Kateřina; Krylová Kateřina; Al Mawiri Abdul, et al. Development of Pulmonary Hypertension in an Infant Treated With Diazoxide for Hyperinsulinism, a Case Report and Literature Review. Am. J. Pediatr. 2015, 1(1), 1-3. doi: 10.11648/j.ajp.20150101.11

    Copy | Download

    AMA Style

    Albahri Ziad, Lukeš Antonín, Mynářová Kateřina, Krylová Kateřina, Al Mawiri Abdul, et al. Development of Pulmonary Hypertension in an Infant Treated With Diazoxide for Hyperinsulinism, a Case Report and Literature Review. Am J Pediatr. 2015;1(1):1-3. doi: 10.11648/j.ajp.20150101.11

    Copy | Download

  • @article{10.11648/j.ajp.20150101.11,
      author = {Albahri Ziad and Lukeš Antonín and Mynářová Kateřina and Krylová Kateřina and Al Mawiri Abdul and Hussain Khaled and Neumann David},
      title = {Development of Pulmonary Hypertension in an Infant Treated With Diazoxide for Hyperinsulinism, a Case Report and Literature Review},
      journal = {American Journal of Pediatrics},
      volume = {1},
      number = {1},
      pages = {1-3},
      doi = {10.11648/j.ajp.20150101.11},
      url = {https://doi.org/10.11648/j.ajp.20150101.11},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ajp.20150101.11},
      abstract = {Congenital hyperinsulinism (CHI) is heterogeneous disorder in the neonatal period characterized by inappropriate insulin secretion in the presence of hypoglycemia. Known etiologies include inactivating mutations of the KATP channel. Its management can be extremely complicated, and may involve medical therapy and surgery. We describe a full term baby male at one month-old without dysmorphic features or congenital anomalies, the baby was presented with asymptomatic hypoglycemia by routine screening at the age of 1.5 hour of life, he was treated with diazoxide for prolonged neonatal hyperinsulinism. Tolerance of diazoxide is usually excellent, but several adverse effects of this drug have been described. During diazoxide therapy he presented with tachycardia and low oxygen saturation, the baby became dyspnoeic with fluid retention and facial edema. Echocardiography showed moderate pulmonary hypertension. Diazoxide was withdrawn, his clinical status and pulmonary hypertension dramatically improved and returned to baseline.},
     year = {2015}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Development of Pulmonary Hypertension in an Infant Treated With Diazoxide for Hyperinsulinism, a Case Report and Literature Review
    AU  - Albahri Ziad
    AU  - Lukeš Antonín
    AU  - Mynářová Kateřina
    AU  - Krylová Kateřina
    AU  - Al Mawiri Abdul
    AU  - Hussain Khaled
    AU  - Neumann David
    Y1  - 2015/07/23
    PY  - 2015
    N1  - https://doi.org/10.11648/j.ajp.20150101.11
    DO  - 10.11648/j.ajp.20150101.11
    T2  - American Journal of Pediatrics
    JF  - American Journal of Pediatrics
    JO  - American Journal of Pediatrics
    SP  - 1
    EP  - 3
    PB  - Science Publishing Group
    SN  - 2472-0909
    UR  - https://doi.org/10.11648/j.ajp.20150101.11
    AB  - Congenital hyperinsulinism (CHI) is heterogeneous disorder in the neonatal period characterized by inappropriate insulin secretion in the presence of hypoglycemia. Known etiologies include inactivating mutations of the KATP channel. Its management can be extremely complicated, and may involve medical therapy and surgery. We describe a full term baby male at one month-old without dysmorphic features or congenital anomalies, the baby was presented with asymptomatic hypoglycemia by routine screening at the age of 1.5 hour of life, he was treated with diazoxide for prolonged neonatal hyperinsulinism. Tolerance of diazoxide is usually excellent, but several adverse effects of this drug have been described. During diazoxide therapy he presented with tachycardia and low oxygen saturation, the baby became dyspnoeic with fluid retention and facial edema. Echocardiography showed moderate pulmonary hypertension. Diazoxide was withdrawn, his clinical status and pulmonary hypertension dramatically improved and returned to baseline.
    VL  - 1
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Department of Pediatrics, Faculty Hospital, Charles University, Hradec Kralove, Czech Republic

  • Internal medicine- Faculty Hospital, Charles University, Hradec Kralove, Czech Republic

  • Department of Paediatric Endocrinology, Institute of Child Health, University College, London, United Kingdom

  • Department of Pediatrics, Faculty Hospital, Charles University, Hradec Kralove, Czech Republic

  • Section